Lexicon Pharmaceuticals Inc. announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in the treatment of diabetic peripheral neuropathic pain (DPNP). The FDA raised no objections to advancing pilavapadin into Phase 3 development. The Phase 3 program will include two placebo-controlled, 12-week, two-arm registrational studies evaluating a 10 mg daily dose compared to placebo. The primary endpoint will be the change in average daily pain score from baseline to Week 12. Results of the Phase 3 studies have not yet been presented and are expected in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9629396-en) on January 21, 2026, and is solely responsible for the information contained therein.